Return to The CPNP Perspective issue main page.< Previous Article  Next Article >

Bob Haight, PharmD, BCPP
2020 CPNP Programming Committee Chair

The 2020 CPNP Annual Meeting’s, pre-meeting workshop, “Applying Pharmacogenomics to Clinical Practice,” will provide attendees with resources to interpret a pharmacogenomics report and review results with patients and providers. Furthermore this workshop will discuss evidence supporting the testing and discuss current FDA guidance regarding pharmacogenomics testing. The workshop will be held on Sunday, April 26 from 8:00 – 11:15 AM. The session with be led by Dr. Jeff Bishop and Dr. Vicki Ellingrod.

There has been significant growth in the use of pharmacogenomics (PGx) testing applied to the prescribing of psychiatric medications. Patients and providers may be unfamiliar with PGx tests, including resources available to aid in interpretation, as well as how to effectively communicate with patients and other providers about the reasons to (or not to test) and interpretation of the results. With the advent of direct to consumer testing options, providers may also be uncertain of what to do when presented with a testing result, including understanding the evidence behind the results included.

Professional organizations have been somewhat resistant to include PGx testing into treatment guidelines for common psychiatric diagnoses. However, the Clinical Pharmacogenetics Implementation Consortium (CPIC) was formed to aid clinicians in their interpretation of PGx results when testing has already occurred, through the release of several guidelines focused on psychiatric medications. Furthermore, providers may not be comfortable counseling patients on PGx results due to their lack of direct experience with the tests. Therefore, this program will be geared toward the novice learner, and work to build and enhance pharmacists’ understanding of the current state of evidence for incorporating pharmacogenomics into patient care plans.

Pharmacists who attend the pre-meeting workshop will be able to:

  1. Review current evidence behind the use of pharmacogenomics (PGx) testing for patients prescribed psychiatric and neurologic medications
  2. Discuss the literature regarding the genes/drug pairs commonly included on PGx tests, as well as the guidelines from Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and the Dutch Pharmacogenetics Working Group (DPWG) for testing result interpretation.
  3. Interpret PGx testing results and use results to inform therapeutic recommendations.
  4. Demonstrate patient counseling skills regarding communication involving PGx testing.

Speakers

Dr. Jeffrey R Bishop, PharmD, MS, BCPP, FCCP
Associate Professor, Department of Experimental and Clinical Pharmacology (ECP)
Adjunct Associate Professor, Department of Psychiatry
University of Minnesota, Minneapolis, MN

Dr. Bishop is associate professor of pharmacy and psychiatry at the University of Minnesota. In this role he conducts psychopharmacology and pharmacogenomics research with a focus on examining genetic relationships with symptom improvement, side effects, and cognitive effects of medications. Dr. Bishop provides clinical and didactic education to pharmacy and medical trainees, and is also involved with clinical consultations regarding the use of pharmacogenomic tests in psychiatry clinics. He is a contributing member to the Clinical Pharmacogenomics Implementation Consortium, the University of Minnesota Precision Medicine and Health Consortium, and the Implementation of Genomics in Practice (IGNITE) network. Dr. Bishop earned a degree in biology at Luther College and went on to complete his Doctor of Pharmacy degree at the University of Iowa. Subsequently he completed a fellowship in clinical psychopharmacology and pharmacogenetics at the University of Iowa College of Pharmacy as well as a master’s degree in Clinical Investigation through the University of Iowa College of Medicine. His research work is currently supported through local, foundation, and NIH funding mechanisms.

Dr. Vicki L. Ellingrod, PharmD, FCCP
Associate Dean for Research and John Gideon Searle Professor of Clinical and Translational Pharmacy, College of Pharmacy
Professor of Psychiatry and Adjunct Professor of Psychology
Associate Director, Michigan Institute for Clinical and Health Research (MICHR) and Director of the Education and Mentoring Group
University of Michigan, Ann Arbor, MI

Vicki L. Ellingrod, Pharm.D., FCCP, is the Associate Dean for Research and Graduate Education in the College of Pharmacy at the University of Michigan. She is also a professor of Psychiatry and Psychology. Within the University of Michigan, she serves as associate director of the Michigan Institute for Clinical and Health Research (MICHR), which provides training to other health professionals wanting training to do clinical research. She obtained her bachelors and PharmD from the University of Minnesota and then completed a postdoctoral fellowship in psychopharmacology/pharmacogenetics at the University of Iowa, followed by joining the faculty there as an assistant professor. Her research has focused on identification of genetic markers related to drug response in mental illness and has been funded by NIMH (National Institute of Mental Health) the FDA, and industry. Prior to joining the faculty at the University of Michigan, Dr. Ellingrod was a practicing clinical pharmacist working on the medical psychiatry unit at the University of Iowa Hospitals and Clinics. Dr. Ellingrod is a founding member of the College of Psychiatric and Neurologic Pharmacists and a full member of the American College of Neuropsychopharmacology (ACNP). She also serves as scientific editor for Pharmacotherapy and is an editor on the DiPiro textbook Pharmacotherapy, a pathophysiologic approach.

Return to The CPNP Perspective issue main page.< Previous Article  Next Article >